Welcome to Bio-Link
Bio-Link is a life sciences business development company which facilitates partnerships based on technology review, project management, business development and deal negotiation. Bio-Link has offices in Melbourne and Sydney.
Our clients include Australian biotech companies and medical research institutes as well as organisations located outside Australia. Our portfolio extends across small molecule and peptide drug candidates, genetic and protein biomarkers and other leading technologies.
Bio-Link adds value to the commercialisation process through critical assessment of patents, packaging of pre-clinical and clinical data, technology marketing and identification and engagement with potential collaborators, licensees, or investors.
Our team has experience in therapeutics and diagnostics and has been involved in a number of commercial transactions in the USA, Europe and Australia.
Please explore this website to gain more information about our team, our clients and our portfolio.
5th February 2013 - Bio-Link Engaged by Phylogica Ltd.
Bio-Link has been engaged by Phylogica Ltd. (ASX: PYC, XETRA: PH7), to provide business development services for a family of its anti-inflammatory Phylomer® peptides, which target the AP-1 pathway and have demonstrated efficacy in multiple preclinical models of stroke, traumatic brain injury and acute respiratory distress syndrome (ARDS). Click here for the full press release.
25th October 2012 - Strategic Alliance with GlobalData
Bio-Link, an international business development company based in Australia, and GlobalData, an international market research organization based in the UK, have entered into a strategic cross-marketing alliance regarding novel drug discovery programs and technologies.
2nd October 2012 - Deal Announcement
Bio-Link has facilitated an alliance between Les Laboratoires Servier (France) and the Florey Institute of Neuroscience and Mental Health together with its collaborative partners St. Vincent's Institute of Medical Research and Monash University around the novel target IRAP for the therapeutic treatment of neurodegenerative disorders. Click here for the full press release
19th April 2012 - Deal Announcement
Bio-Link has facilitated a commercial arrangement between the Lions Eye Institute (LEI), Perth and Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) around the Akimba model of diabetic retinopathy developed by Prof. Elizabeth Rackoczy and her colleagues at LEI.